ProPhase Labs, Inc. Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations
ProPhase Labs, Inc. (PRPH) reported Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations of $12.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-31.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems · last filed 2021-03-31
- ProPhase Labs, Inc. income tax expense (benefit), continuing operations, discontinued operations for fiscal 2020 was $12.00K.
- ProPhase Labs, Inc. income tax expense (benefit), continuing operations, discontinued operations for fiscal 2018 was $103.00K, a 95.07% decline from fiscal 2017.
- ProPhase Labs, Inc. income tax expense (benefit), continuing operations, discontinued operations for fiscal 2017 was $2.09M.
- ProPhase Labs, Inc. income tax expense (benefit), continuing operations, discontinued operations for fiscal 2014 was $0.00.
| Period end | Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations 12 month | Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations 12 month as first filed |
|---|---|---|
| 2020-12-31 | $12.00K 10-K · filed 2021-03-31 | |
| 2018-12-31 | $103.00K 10-K · filed 2020-03-26 | |
| 2017-12-31 | $2.09M 10-K · filed 2019-03-26 | $848.00K 10-K · filed 2018-03-28 |
| 2014-12-31 | $0.00 10-K · filed 2015-03-27 | |
| 2013-12-31 | $0.00 10-K · filed 2015-03-27 | |
| 2012-12-31 | $0.00 10-K · filed 2015-03-27 | |
| 2011-12-31 | $0.00 10-K · filed 2014-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |